Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-06-04, Stock:NVS, The news for the past five days is as follows:
2021-05-27: NEWS1: 10 Best Dividend Stocks to Buy According to Cathie Wood.NEWS2: Novartis (NVS) & Molecular Partners Initiate Study for COVID-19.NEWS3: Novartis and Molecular Partners Begin EMPATHY Clinical Trial.NEWS4: Novartis, Molecular Partners Initiate Global Trial For COVID-19 Treatment.NEWS5: Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19.
2021-05-28: NEWS1: Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program.NEWS2: Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies.
2021-06-01: NEWS1: Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis.NEWS2: Novartis Terminates Three Beovu Studies in Ocular Disorders Citing Patient Safety.
2021-06-02: NEWS1: Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma.NEWS2: Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients.NEWS3: Novartis's Late-stage Study On Cosentyx Hits Primary Endpoint Goal In Juvenile Idiopathic Arthritis.NEWS4: Novartis's Cosentyx Wins FDA Approval For Psoriasis In Pediatric Patients.NEWS5: Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021.
2021-06-03: NEWS1: Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera.NEWS2: Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months.NEWS3: Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study.

Answer: Rise